Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes
Objectives The aim of this study was to investigate the efficacy, tolerability, safety, and impact on quality of life (QoL) and functional status of vortioxetine treatment for patients with generalised anxiety disorder (GAD) by performing a meta-analysis of randomised controlled trials (RCTs).Design...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-11-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/9/11/e033161.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846149547537989632 |
|---|---|
| author | Qian Yang Bin Qin Guangsu Huang Mingjun Zhao Wen Gao Mingxiu Yang |
| author_facet | Qian Yang Bin Qin Guangsu Huang Mingjun Zhao Wen Gao Mingxiu Yang |
| author_sort | Qian Yang |
| collection | DOAJ |
| description | Objectives The aim of this study was to investigate the efficacy, tolerability, safety, and impact on quality of life (QoL) and functional status of vortioxetine treatment for patients with generalised anxiety disorder (GAD) by performing a meta-analysis of randomised controlled trials (RCTs).Design Systematic review and meta-analysis.Data sources Data mining was conducted in January 2019 across PubMed, EMBASE, PsycINFO, Cochrane Central Register of Controlled Trials Cochrane Library, Web of science and ClinicalTrials.gov.Eligibility criteria for selecting studies All published RCTs, which assessed the effect of vortioxetine treatment for patients with GAD when compared with a placebo group, were included.Data extraction and synthesis Relevant data were extracted and synthesised narratively. Results were expressed as standardised mean differences or ORs with 95% CIs.Results Our meta-analysis showed that multiple doses (2.5, 5 and 10 mg/day) of vortioxetine did not significantly improve the response rates, compared with placebo (OR 1.16, 95% CI 0.84 to 1.60, p=0.38; OR 1.41, 95% CI 0.82 to 2.41, p=0.21; and OR 1.05, 95% CI 0.76 to 1.46, p=0.75). Moreover, there was no statistically significant difference regarding the remission rates, discontinuation for any reason rates, discontinuation due to adverse events rates, Short-Form 36 Health Survey scores or Sheehan Disability Scale scores between administration of multiple doses (2.5, 5 and 10 mg/day) of vortioxetine and placebo.Conclusions Although our results suggest that vortioxetine did not improve the GAD symptoms, QoL and functional status impairment of patients with GAD, it was safe and well tolerated. Clinicians should interpret and translate our data with caution, as the meta-analysis was based on a limited number of RCTs. |
| format | Article |
| id | doaj-art-992be94d5d414892974c3176c5a04472 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2019-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-992be94d5d414892974c3176c5a044722024-11-29T15:15:09ZengBMJ Publishing GroupBMJ Open2044-60552019-11-0191110.1136/bmjopen-2019-033161Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomesQian Yang0Bin Qin1Guangsu Huang2Mingjun Zhao3Wen Gao4Mingxiu Yang53 College of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaDepartment of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China2 Department of Neurology, Affiliated Liuzhou General Hospital of Guangxi University of Science and Technology, Liuzhou, China3 Department of Pharmacy, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, ChinaGI Department, Peking University First Hospital, Beijing, Beijing, China2 Department of Neurology, Affiliated Liuzhou General Hospital of Guangxi University of Science and Technology, Liuzhou, ChinaObjectives The aim of this study was to investigate the efficacy, tolerability, safety, and impact on quality of life (QoL) and functional status of vortioxetine treatment for patients with generalised anxiety disorder (GAD) by performing a meta-analysis of randomised controlled trials (RCTs).Design Systematic review and meta-analysis.Data sources Data mining was conducted in January 2019 across PubMed, EMBASE, PsycINFO, Cochrane Central Register of Controlled Trials Cochrane Library, Web of science and ClinicalTrials.gov.Eligibility criteria for selecting studies All published RCTs, which assessed the effect of vortioxetine treatment for patients with GAD when compared with a placebo group, were included.Data extraction and synthesis Relevant data were extracted and synthesised narratively. Results were expressed as standardised mean differences or ORs with 95% CIs.Results Our meta-analysis showed that multiple doses (2.5, 5 and 10 mg/day) of vortioxetine did not significantly improve the response rates, compared with placebo (OR 1.16, 95% CI 0.84 to 1.60, p=0.38; OR 1.41, 95% CI 0.82 to 2.41, p=0.21; and OR 1.05, 95% CI 0.76 to 1.46, p=0.75). Moreover, there was no statistically significant difference regarding the remission rates, discontinuation for any reason rates, discontinuation due to adverse events rates, Short-Form 36 Health Survey scores or Sheehan Disability Scale scores between administration of multiple doses (2.5, 5 and 10 mg/day) of vortioxetine and placebo.Conclusions Although our results suggest that vortioxetine did not improve the GAD symptoms, QoL and functional status impairment of patients with GAD, it was safe and well tolerated. Clinicians should interpret and translate our data with caution, as the meta-analysis was based on a limited number of RCTs.https://bmjopen.bmj.com/content/9/11/e033161.full |
| spellingShingle | Qian Yang Bin Qin Guangsu Huang Mingjun Zhao Wen Gao Mingxiu Yang Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes BMJ Open |
| title | Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes |
| title_full | Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes |
| title_fullStr | Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes |
| title_full_unstemmed | Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes |
| title_short | Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes |
| title_sort | vortioxetine treatment for generalised anxiety disorder a meta analysis of anxiety quality of life and safety outcomes |
| url | https://bmjopen.bmj.com/content/9/11/e033161.full |
| work_keys_str_mv | AT qianyang vortioxetinetreatmentforgeneralisedanxietydisorderametaanalysisofanxietyqualityoflifeandsafetyoutcomes AT binqin vortioxetinetreatmentforgeneralisedanxietydisorderametaanalysisofanxietyqualityoflifeandsafetyoutcomes AT guangsuhuang vortioxetinetreatmentforgeneralisedanxietydisorderametaanalysisofanxietyqualityoflifeandsafetyoutcomes AT mingjunzhao vortioxetinetreatmentforgeneralisedanxietydisorderametaanalysisofanxietyqualityoflifeandsafetyoutcomes AT wengao vortioxetinetreatmentforgeneralisedanxietydisorderametaanalysisofanxietyqualityoflifeandsafetyoutcomes AT mingxiuyang vortioxetinetreatmentforgeneralisedanxietydisorderametaanalysisofanxietyqualityoflifeandsafetyoutcomes |